Navigation Links
PharmAthene to Delay Release of Full Year 2007 Financial Results
Date:3/20/2008

ANNAPOLIS, Md., March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, today reported the company will delay its earnings release for the full year ended December 31, 2007. The earnings release was previously scheduled for today, March 20, 2008. PharmAthene will schedule the new date and time of its earnings release and conference call at a later time.

The conference call originally scheduled to discuss earnings will occur at 4:30 pm E.T. today and will focus on the Avecia acquisition announced earlier today.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
2. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
3. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
4. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
10. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2020)... , ... February 03, 2020 , ... ... in Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor to ... is a best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping ...
(Date:1/27/2020)... ... 2020 , ... Cerebyte, the leader in “instant mentoring” solutions ... the availability of neuroscience of transformational leadership workshops. These highly interactive, hands-on workshops ... and change research to become great transformational leaders. The workshops are ...
(Date:1/24/2020)... ... January 24, 2020 , ... Sierra Instruments, global leader in ... controllers ideal for BioPharm OEMS. Sierra also announces RedyCompact™ flow ... instruments employ high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable no-drift ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and ... editing. The partners have agreed to co-develop and market a portfolio of CRISPR ... pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded ...
Breaking Biology Technology:
(Date:1/30/2020)... ... ... Accelera Canada , a full-service firm delivering end-to-end commercialization services to emerging ... the company has opened the doors of its first office in Toronto, following two ... so thrilled to now have all our partners and their highly skilled teams under ...
(Date:1/29/2020)... ... January 29, 2020 , ... VGXI, a world leading ... a DNA vaccine against the novel coronavirus (2019-nCoV) that has recently emerged in ... to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) will fund ...
(Date:1/27/2020)... ... , ... On Thursday, February 20, 2020 at 10am EST (3pm GMT/UK), join ... Richard Castle, Global Account Manager Medical Device at PRISYM ID for an ... timing deadlines, best practices in creating and submitting product data and best practices in ...
Breaking Biology News(10 mins):